Reporter brief
(MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study
What happened
Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No effect sizes or outcome data were reported, so efficacy of metformin on any measured parameter cannot be assessed from this abstract. This is a pilot/feasibility study, which typically prioritizes recruitment and protocol adherence rather than demonstrating clinical benefit. As a pilot study, results cannot be generalized or used to establish whether metformin affects longevity or aging biomarkers in elderly populations.
Study design and sample
Rct; Human.
Elderly
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Nov 17, 2022
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.